Abstract
The TRPV1 vanilloid receptor, first cloned and characterized in 1997, is a non selective cation channel expressed in primary sensory neurons, and is a key pain sensor and integrator. Activators of this receptor are varied and include capsaicin, the pungent phenolic principle from hot chilli peppers, endogenous lipid anandamide, noxious heat, and low extracellular pH. Agonists of the TRPV1 receptor have been investigated for development due to their analgesic effect that results from the receptor desensitization. However, all agonists including capsaicin cause initial burning effect, and have the potential for other undesirable effects, which complicates effective therapy. The development of animal pain models involving TRPV1 receptor blockade through small molecules and characterization of TRPV1 knockout mice models in recent years has provided a compelling argument in favor of pursuing the development of selective TRPV1 antagonists as novel analgesic agents. This article will provide an overview of the various chemical classes of agonists and antagonists of TRPV1 receptor along with their therapeutic potential and possible side effects.
Keywords: TRPV1 receptor antagonists, vanilloids, structure activity relationships, agonist binding site, pain modulation
Current Bioactive Compounds
Title: Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Volume: 4 Issue: 2
Author(s): Vijaya L. Korlipara
Affiliation:
Keywords: TRPV1 receptor antagonists, vanilloids, structure activity relationships, agonist binding site, pain modulation
Abstract: The TRPV1 vanilloid receptor, first cloned and characterized in 1997, is a non selective cation channel expressed in primary sensory neurons, and is a key pain sensor and integrator. Activators of this receptor are varied and include capsaicin, the pungent phenolic principle from hot chilli peppers, endogenous lipid anandamide, noxious heat, and low extracellular pH. Agonists of the TRPV1 receptor have been investigated for development due to their analgesic effect that results from the receptor desensitization. However, all agonists including capsaicin cause initial burning effect, and have the potential for other undesirable effects, which complicates effective therapy. The development of animal pain models involving TRPV1 receptor blockade through small molecules and characterization of TRPV1 knockout mice models in recent years has provided a compelling argument in favor of pursuing the development of selective TRPV1 antagonists as novel analgesic agents. This article will provide an overview of the various chemical classes of agonists and antagonists of TRPV1 receptor along with their therapeutic potential and possible side effects.
Export Options
About this article
Cite this article as:
Korlipara L. Vijaya, Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294235
DOI https://dx.doi.org/10.2174/157340708785294235 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) Opioids and Cannabinoids Interactions: Involvement in Pain Management
Current Drug Targets Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Nanoplatforms for Delivery of siRNA to the Eye
Current Pharmaceutical Design Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Oxyprenylated Secondary Metabolites as Modulators of Lipid and Sugar Metabolism
Current Topics in Medicinal Chemistry Mechanisms of Neuronal Cell Death in AGE-exposed Retinas - Research and Literature Review
Current Diabetes Reviews Editorial: Advances in Alzheimer Therapy: Something Old, Something New, Something Borrowed, Something Blue
Current Alzheimer Research RAGE, Diabetes, and the Nervous System
Current Molecular Medicine Review of Erectile Dysfunction in Diabetic Animal Models
Current Diabetes Reviews The Antidiabetic PPARγ Ligands: An Update on Compounds in Development
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review
Current Alzheimer Research Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design A Review on Electrocardiographic Changes in Diabetic Patients
Current Diabetes Reviews Mechanism Underlying the Formation of a Cluster of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets A Hopeful Prospect of Riociguat as a Soluble Guanylate Cyclase Stimulator for Management of Pressure Ulcers
Current Drug Discovery Technologies Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings
Current Medicinal Chemistry